- Home
- ELVN vs JFR Comparison
ELVN vs JFR Comparison
Compare ELVN & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- JFR
- Stock Information
- Founded
- ELVN 2016
- JFR 2004
- Country
- ELVN United States
- JFR United States
- Employees
- ELVN N/A
- JFR N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- JFR Trusts Except Educational Religious and Charitable
- Sector
- ELVN Health Care
- JFR Finance
- Exchange
- ELVN Nasdaq
- JFR Nasdaq
- Market Cap
- ELVN 1.0B
- JFR 1.2B
- IPO Year
- ELVN 2020
- JFR N/A
- Fundamental
- Price
- ELVN $21.60
- JFR $8.54
- Analyst Decision
- ELVN Strong Buy
- JFR
- Analyst Count
- ELVN 5
- JFR 0
- Target Price
- ELVN $37.80
- JFR N/A
- AVG Volume (30 Days)
- ELVN 269.1K
- JFR 621.7K
- Earning Date
- ELVN 03-13-2025
- JFR 01-01-0001
- Dividend Yield
- ELVN N/A
- JFR 11.31%
- EPS Growth
- ELVN N/A
- JFR N/A
- EPS
- ELVN N/A
- JFR N/A
- Revenue
- ELVN N/A
- JFR N/A
- Revenue This Year
- ELVN N/A
- JFR N/A
- Revenue Next Year
- ELVN N/A
- JFR N/A
- P/E Ratio
- ELVN N/A
- JFR N/A
- Revenue Growth
- ELVN N/A
- JFR N/A
- 52 Week Low
- ELVN $10.90
- JFR $7.61
- 52 Week High
- ELVN $30.03
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- ELVN 47.03
- JFR 36.60
- Support Level
- ELVN $20.40
- JFR $8.45
- Resistance Level
- ELVN $22.42
- JFR $8.66
- Average True Range (ATR)
- ELVN 1.25
- JFR 0.09
- MACD
- ELVN 0.06
- JFR -0.00
- Stochastic Oscillator
- ELVN 59.59
- JFR 29.35
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.